Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Fig. 3

Effect on APTT, blood lipids and AST of weekly IV dosing in beagle dogs and humans (patients in the 100 mg cohort). APTT (a), cholesterol (b), triglycerides (c) and AST (d) were measured in the blood of dogs after 5 pixatimod doses (weekly dosing). Treatment averages indicated with short solid horizontal lines. Corresponding data from the six 100 mg patients for these 4 parameters are presented over time. Dotted lines represent upper limit of the normal range for each parameter. * = P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus control (Kruskal-Wallis test)

Back to article page